Indivior Pharmaceuticals, Inc.
INDV
$33.34
$0.742.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.24B | 1.18B | 1.17B | 1.17B | 1.19B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24B | 1.18B | 1.17B | 1.17B | 1.19B |
| Cost of Revenue | 198.00M | 191.00M | 201.00M | 228.00M | 222.00M |
| Gross Profit | 1.04B | 990.00M | 973.00M | 943.00M | 967.00M |
| SG&A Expenses | 578.00M | 598.00M | 598.00M | 592.00M | 603.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.00M | -10.00M | -5.00M | -5.00M | -5.00M |
| Total Operating Expenses | 852.00M | 873.00M | 890.00M | 916.00M | 927.00M |
| Operating Income | 388.00M | 308.00M | 284.00M | 255.00M | 262.00M |
| Income Before Tax | 238.00M | 195.00M | 188.00M | 6.00M | 20.00M |
| Income Tax Expenses | 29.00M | 67.00M | 80.00M | 13.00M | 13.00M |
| Earnings from Continuing Operations | 209.00 | 128.00 | 108.00 | -7.00 | 7.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 209.00M | 128.00M | 108.00M | -7.00M | 7.00M |
| EBIT | 388.00M | 308.00M | 284.00M | 255.00M | 262.00M |
| EBITDA | 398.00M | 318.00M | 295.00M | 268.00M | 275.00M |
| EPS Basic | 1.68 | 1.02 | 0.86 | -0.01 | 0.06 |
| Normalized Basic EPS | 1.82 | 1.37 | 1.24 | 1.11 | 1.15 |
| EPS Diluted | 1.64 | 1.01 | 0.84 | -0.02 | 0.05 |
| Normalized Diluted EPS | 1.77 | 1.35 | 1.23 | 1.10 | 1.14 |
| Average Basic Shares Outstanding | 498.39M | 500.61M | 507.61M | 517.61M | 529.61M |
| Average Diluted Shares Outstanding | 509.11M | 508.08M | 512.08M | 521.08M | 533.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |